What is Alnylam Pharmaceuticals's business segments — R&D?

Alnylam Pharmaceuticals (ALNY) reported business segments — R&D of $413.13M in Q2 2026.

What does business segments — R&D mean?

This metric represents the total operating expenses allocated to research and development activities within the company's primary business segment. It captures investments in clinical trials, drug discovery, and the advancement of the therapeutic pipeline. Monitoring this spend is critical for assessing the company's commitment to long-term innovation and the sustainability of its product development lifecycle.

Alnylam Pharmaceuticals ALNY Business Segments — R&D

Similar metrics at other companies

NRIXReportable Segment — R&D

$87.65M+12.2%

AGIOReportable Segment — R&D

$25.85M-13.3%

IMVTReportable Segment — R&D

$29.22M-6.2%

BCAXReportable Segment — R&D

$47.5M+38.4%

ZYMEReportable Segment — R&D

$34.46M-3.6%

VRDNReportable Segment — Segment research and development expense

$71.74M+1.0%

Other financials

Income statement

See full

Revenue$1.3B+66.9%

Gross profit$992.7M+57.2%

Operating income$231.4M+1,529%

Net income$164.5M+348%

EPS (diluted)$1.21+337%

Balance sheet

See full

Cash & equivalents$1.7B+53.2%

Total debt$256.4M-5.2%

Total equity$1.4B+440%

Total assets$5.6B+21.7%

Cash flow

See full

Operating cash flow$326.7M+113%

CapEx$34.7M+143%

Free cash flow$292.0M+109%

Valuation

See full

Market cap$38.51B-10.7%

Enterprise value$37.05B-12.3%

P/E52.5×—

P/S8×-9.5×

Profitability

See full

Gross margin79.8%-4.1pp

Operating margin20.8%+16.5pp

Net margin15.3%+10.7pp

FCF margin16.5%+14.8pp

Returns & leverage

See full

Return on equity91.4%—

Debt / equity0.2×-0.9×

Current ratio3.1×+0.3×

Where this comes from

Reported directly by Alnylam Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alnylam Pharmaceuticals's business segments — r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alnylam Pharmaceuticals's business segments — R&D?: Alnylam Pharmaceuticals (ALNY) reported business segments — R&D of $413.13M in Q2 2026.
What does business segments — R&D mean?: This metric represents the total operating expenses allocated to research and development activities within the company's primary business segment. It captures investments in clinical trials, drug discovery, and the advancement of the therapeutic pipeline. Monitoring this spend is critical for assessing the company's commitment to long-term innovation and the sustainability of its product development lifecycle.